glp-1 medications zepbound FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - Eli Lilly CVS Restores Coverage of Lilly's

Theres also Zepbound, Mounjaro, Trulicity and Victoza and many more on the horizon for people with obesity or Type 2 diabetes

In type 2 diabetes-related cervical cancer tissues, a high-glucose microenvironment induces the upregulation of PSMA2, phosphorylated IB, and phosphorylated P65 expression, thereby promoting tumor progression, while Ex-4 can effectively inhibit this pathological process [120]

UW Medicine

TL;DR - What You Need to Know About FeelGood GLP-1 in 60 Seconds FeelGood GLP-1 is a telehealth platform connecting patients with licensed medical providers for evaluation and, when clinically appropriate, access to compounded GLP-1 injections starting at $149 per month - in a category where FDA formally proposed in April 2026 removing semaglutide and tirzepatide from the 503B outsourcing bulks list - with a public comment period open through June 2026

There is a large pool of GLP-1 candidates

Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 OZEM HoldingsNovo Nordisk A/S (NYSE:NVO)Holding Weight: 12.85%Eli Lilly and Company (NYSE:LLY)Holding Weight: 12.51%Pfizer (NYSE:PFE)Holding Weight: 6.25%Viking Therapeutics (NASDAQ:VKTX)Holding Weight: 6.01%CSPC Pharmaceutical Group LimitedHolding Weight: 5.80%Kailera Therapeutics (NASDAQ:KLRA)Holding Weight: 5.76%Chugai Pharmaceutical Co LtdHolding Weight: 4.27%Ascletis Pharma Inc.Holding Weight: 4.17%Zealand Pharma A/SHolding Weight: 3.79%Amgen (NASDAQ:AMGN)Holding Weight: 3.75%Full Holdings DetailsOZEM Sector ExposureOZEM Industry Exposure This page (NASDAQ:OZEM) was last updated on 7/18/2026 by MarketBeat.com Staff